Summary
BeOne Medicines Ltd. (ONC) has filed its 2023 Interim Report with the Shanghai Stock Exchange, providing financial information for the six months ended June 30, 2023. This report was prepared in accordance with China Accounting Standards (CAS) and other PRC regulations. Importantly, the filing includes additional financial details, specifically research and development expenses broken down by key products and projects, prepared under U.S. GAAP. This U.S. GAAP information, along with a summary of the differences between PRC GAAP and U.S. GAAP, is attached as Exhibit 99.1, offering investors a clearer view of R&D investment aligned with U.S. reporting standards. While the full interim report is available in Chinese on the Shanghai Stock Exchange website, investors should note that the information furnished in this 8-K, particularly Exhibit 99.1, is intended for informational purposes and is not deemed 'filed' under U.S. securities laws. This distinction is crucial for understanding the legal and reporting implications of the provided data.
Key Highlights
- 1BeOne Medicines Ltd. filed its 2023 Interim Report for the six months ended June 30, 2023.
- 2The report was submitted to the Shanghai Stock Exchange's STAR Market and prepared according to PRC accounting standards (CAS).
- 3Key U.S. GAAP financial information, specifically R&D expenses by product and project, is provided as Exhibit 99.1.
- 4A summary of material differences between PRC GAAP and U.S. GAAP is also included.
- 5Exhibit 99.1 allows investors to analyze R&D spending in a format familiar to U.S. GAAP.
- 6The STAR Interim Report is available in Chinese on the Shanghai Stock Exchange website.
- 7Information furnished in this 8-K is for informational purposes and not deemed 'filed' under U.S. securities laws.